arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

download Export Data

Contineum Therapeutics, Inc.

CTNM

$15.06 ▼ -0.27 (-1.76%) at close

15 Visible periods

24 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Neutral

auto_awesome

Analytical Summary

Contineum Therapeutics, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $564.3M

Dividend Yield —

Revenue Growth —

Op. Margin None

ROIC -5.7% ↘

FCF / Share $-0.31 ↗

Trailing P/E —

Price / Book 2.4x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

15-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-14.46M

↑ +9.6% —

FCF / Share Free cash flow per share

$-0.31

↑ +30.8% —

Health Breakdown

Returns ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
EPS Growth YoY (%)	35.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	37.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	14.0% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	-12.5% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-59.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	82.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-7.5% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	85.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	-67.5% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	9.6% Fair ↑ Fair Improving Year-over-year change in net income	9.6% Fair ↑ Fair Improving Year-over-year change in net income	-4.1% Weak ↑ Weak Improving Year-over-year change in net income	-90.0% Weak → Weak Stable Year-over-year change in net income	-90.0% Weak ↓ Weak Declining Year-over-year change in net income	-90.0% Weak ↓ Weak Declining Year-over-year change in net income	-87.5% Weak ↓ Weak Declining Year-over-year change in net income	-74.5% Weak → Weak Stable Year-over-year change in net income	-74.5% Weak Weak Year-over-year change in net income	-74.5% Weak Weak Year-over-year change in net income	—	—	—	—	—
FCF Growth YoY (%)	—	20.6% Good Good Year-over-year change in free cash flow	—	—	—	83.7% Excellent Excellent Year-over-year change in free cash flow	—	—	—	-47.4% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	—	—	—	—	—	—	—	77.9% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+419%)	—	—
Effective Tax Rate (%) (%)	—	—	—	—	—	—	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	2.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	1.9% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	1.7% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	—	—	—	—	—	—	—	—	—	—	—	—	-9.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-180%)	—	—
FCF Margin (%) (%)	—	—	—	—	—	—	—	—	—	—	—	—	81.3% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	—	—
FCF / Net Income (x)	0.80x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.15x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	—	0.90x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	0.96x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.42x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	1.12x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	-8.43x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	1.10x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-5.7% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-5.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-5.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-6.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-8.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-7.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-8.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-6.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-5.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	13.1% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	14.0% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	13.0% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	-69.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	5.2% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-7.0% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-6.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-6.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-7.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-9.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-9.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-8.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-6.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-4.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-8.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-7.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-6.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-140%)	-5.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-139%)	-5.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-139%)	-8.9% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-159%)	-9.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-162%)	-8.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-158%)	-7.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-149%)	-4.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-127%)	-3.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-126%)	11.1% Fair ↑ Fair Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-26%)	11.4% Fair ↑ Fair Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-24%)	7.9% Caution ↑ Caution Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-47%)	8.7% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-42%)	4.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-67%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Net Debt (USD)	$-14.71M	$-20.16M	$-75.60M	$-42.63M	$-20.78M	$-22.47M	$-21.94M	$-40.89M	$-77.23M	$-16.26M	$-15.53M	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Revenue per Share (USD)	—	—	—	—	—	—	—	$0.00	$0.00	—	—	$0.00	$21.82	—	—
Basic EPS, GAAP (USD)	$-0.40	$-0.39	$-0.49	$-0.45	$-0.62	$-0.62	$-0.57	$-0.40	$-0.39	$-3.55	$-0.53	$-2.69	$2.56	$-2.12	—
Free Cash Flow per Share (USD)	$-0.31	$-0.44	—	$-0.44	—	$-0.56	—	—	—	$-3.43	—	$-2.32	$17.73	$-2.33	—
Book Value per Share (USD)	$6.40	$6.70	—	$6.42	$6.62	$7.14	—	$8.17	$9.31	$-31.72	—	$-26.30	$-24.19	$-42.79	—
Tangible Book Value per Share (USD)	$6.40	$6.70	—	$6.42	$6.62	$7.14	—	$8.17	$9.31	$-31.72	—	$-26.30	$-24.19	$-42.79	—
Basic Weighted Avg Shares (shares)	37.47M	37.34M	—	28.12M	25.90M	25.87M	—	25.73M	23.36M	2.37M	—	2.32M	2.29M	2.28M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$236.05M	$246.31M	$258.17M	$178.57M	$169.62M	$183.19M	$196.41M	$209.34M	$216.58M	$113.48M	$122.22M	—	—	—	—
Total Equity (USD)	$239.66M	$250.04M	$260.99M	$180.47M	$171.39M	$184.77M	$198.07M	$210.23M	$217.50M	$-75.63M	$-67.94M	$-61.15M	$-55.43M	$-97.46M	$-93.21M

📋 What is driving earnings? 4 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	—	—	—	—	$0.00	$0.00	—	$0.00	$0.00	$50.00M	—	—
Depreciation Expense (USD)	$134.00K	$83.00K	$85.00K	$81.00K	—	$78.00K	$75.00K	—	—	$61.00K	$37.00K	$43.00K	$42.00K	$73.00K	—
Net Income, GAAP (USD)	$-14.46M	$-14.46M	$-15.16M	$-15.99M	$-15.99M	$-15.99M	$-14.56M	$-8.42M	$-8.42M	$-8.42M	$-7.77M	$-4.82M	$-4.82M	$-4.82M	—
Operating Cash Flow (USD)	$-11.50M	$-16.27M	$-13.04M	$-12.20M	—	$-14.41M	$-10.20M	—	—	$-7.97M	$-10.70M	$-5.38M	$40.67M	$-5.24M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 15 quarters

Contineum Therapeutics, Inc.

Analytical Summary

15-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare CTNM with peers